T. Rowe Price Associates’s Tarsus Pharmaceuticals TARS Stock Holding History

T. Rowe Price Associates’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.4M	Sell	260,784 -14,020	-5%	-$896K	﹤0.01%	1198
2026 Q1	$19.3M	Sell	274,804 -243,976	-47%	-$17M	﹤0.01%	1048
2025 Q4	$42.5M	Buy	518,780 +65,923	+15%	+$4.92M	﹤0.01%	855
2025 Q3	$26.9M	Buy	452,857 +68,955	+18%	+$3.39M	﹤0.01%	985
2025 Q2	$15.6M	Sell	383,902 -49,269	-11%	-$2.22M	﹤0.01%	1011
2025 Q1	$22.3M	Sell	433,171 -27,602	-6%	-$1.36M	﹤0.01%	932
2024 Q4	$25.5M	Buy	460,773 +221,458	+93%	+$10.1M	﹤0.01%	933
2024 Q3	$7.87M	Sell	239,315 -51,960	-18%	-$1.46M	﹤0.01%	1185
2024 Q2	$7.92M	Sell	291,275 -56,408	-16%	-$1.9M	﹤0.01%	1144
2024 Q1	$12.6M	Buy	+347,683	New	+$10.2M	﹤0.01%	1063

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates's TARS Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Tarsus Pharmaceuticals (TARS) stake by 5.1% in Q2 2026, selling an estimated $896K and leaving 260,784 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

T. Rowe Price Associates first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $42.5M in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

T. Rowe Price Associates held 260,784 shares of Tarsus Pharmaceuticals worth $16.4M as of Q2 2026.
T. Rowe Price Associates sold 14,020 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $896K.
Tarsus Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1198 holding.
T. Rowe Price Associates first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
T. Rowe Price Associates's Tarsus Pharmaceuticals position peaked at $42.5M in Q4 2025.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.